Drawing on his background in physics and cell mechanics, Ze’ev Bomzon leads a team of researchers at Novocure’s facility in Israel. Ze’ev’s main focus has been on optimizing the delivery of Tumor Treating Fields (TTFields) using physics research.
“We do a lot of simulation, numerical work and experimental work as well, such as measuring TTFields in various situations,” Ze’ev said. “We also continue our research into the mechanism of action of TTFields.”
This work requires partnership with the preclinical teams and researching the electric properties of cells, which are relevant to enhancing the understanding of how TTFields penetrate into the cells.
Yet Ze’ev recognizes the importance not just of the research itself, but also the necessity of effectively explaining Novocure’s technology – which bridges physics and biology – to researchers of various scientific backgrounds.
Additional research, whether done internally or externally, will help inform our therapy and could result in better outcomes for patients.”
“For many people, the concept of an electric field is abstract,” Ze’ev said. “It’s not easy for everyone to comprehend the physics and theory behind it. We’re always developing new tools to educate people.”
Those efforts have begun to bear fruit as more outside institutions have taken notice of the TTFields technology and started to study it in the last several years.
“Additional research, whether done internally or externally, will help inform our therapy and could result in better outcomes for patients,” he said.
It is not only the collaboration with a global community of scientists that motivates Ze’ev, but also the pure sense of discovery.
“I like that science involves exploring new territory and doing new things,” he said.
novocuretrial.com The science of Tumor Treating Fields extends beyond glioblastoma and mesothelioma. Novocure has ongoing or completed clinical trials investigating our therapy in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.